Chicos Celestin, Zirkiyeva Milana, Bandagi Sabiha, Abrudescu Adriana
Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA.
Rheumatology, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA.
Cureus. 2021 Jan 20;13(1):e12825. doi: 10.7759/cureus.12825.
Macrophage activation syndrome (MAS) is a subset of hemophagocytic lymphohistiocytosis (HLH) described in patients with rheumatological disorders. Some triggers of MAS and HLH include infection, malignancy, rheumatological disease, HIV, and rarely medications such as immunosuppressants. In recent medical literature, biologic agents are increasingly recognized as a potential trigger, but the mechanism behind this remains poorly understood. We describe the case of a patient who developed MAS after initiating adalimumab and propose a potential pathophysiological link between biologics and this syndrome.
巨噬细胞活化综合征（MAS）是在风湿性疾病患者中描述的噬血细胞性淋巴组织细胞增生症（HLH）的一个亚型。MAS和HLH的一些触发因素包括感染、恶性肿瘤、风湿性疾病、HIV，以及很少见的药物如免疫抑制剂。在最近的医学文献中，生物制剂越来越被认为是一种潜在的触发因素，但其背后的机制仍知之甚少。我们描述了一例在开始使用阿达木单抗后发生MAS的患者病例，并提出了生物制剂与该综合征之间潜在的病理生理联系。
